Each bar is the last disclosed mark — $1B for Alloy Therapeutics (post-money, Apr 2026) and $2.25B for HistoSonics (basis undisclosed, Aug 2025).
At least one valuation basis is undisclosed, so the two numbers stay side by side, each with its own chip, and no ratio is scored. Both are private: there is no public quote and no Canborsa market on either name.
Alloy Therapeutics' sector is Biotech; HistoSonics's sector is Medical Device.
Alloy Therapeutics is valued at $1B, and HistoSonics at $2.2B.
Alloy Therapeutics' headquarters is in United States; HistoSonics's is in Plymouth, Minnesota.
Alloy Therapeutics is headquartered in United States, and HistoSonics in United States.